The junctional face membrane plays a key role in excitation-contraction coupling in skeletal muscle. A protein of 350 kDa, tentatively identified as a component of the junctional feet, connects transverse tubules to terminal cisternae of sarcoplasmic reticulum [Kawamoto, Brunschwig, Kim & Caswell (1986) Ca2" release indicated that anti-(350 kDa protein) antibodies prevented Ca2"-induced Ca2" release, whereas the ATP-stimulation and the inhibition by Mg2" were not affected. These results suggest that: (i) Ca2+-and doxorubicin-induced Ca2" release is mediated by Ca2" channels which are selectively localized in the junctional face membrane; (ii) the 350 kDa protein is a component of the Ca2"-release channel in native terminal cisternae vesicles; and (iii) the Ca2"-activating site of the channel is separate from other allosteric sites.
INTRODUCTION
The sarcoplasmic reticulum is an intracellular network of membranes which controls the contraction-relaxation cycle of skeletal muscle by raising and lowering the myoplasmic free Ca2" concentration. The sarcoplasmic reticulum consists of two morphologically and functionally distinct portions. The 'free' sarcoplasmic reticulum is formed by longitudinally oriented tubules and non-junctional membranes of terminal cisternae, and is endowed with a Ca2" pump (Jorgensen et al., 1982; Inesi, 1985) . The junctional face membrane is the portion of terminal cisternae directly facing the transverse tubules, the invaginations of the sarcolemma. The transverse tubules and terminal cisternae are connected by feet structures, which cross a gap of 10 nm separating the two membrane compartments (Franzini-Armstrong, 1980) . The subunit of the free structures is a junctional component having a molecular mass of 350 kDa, recently identified as the ryanodine receptor Inui et al., 1987; Lai et al., 1987) . The molecular mass of the feet protein has not yet been determined, and estimates range from 325 to 450 kDa . Throughout the text, the feet protein is also referred to as 350 kDa spanning protein (Kawamoto et al., 1986) , doxorubicin-binding protein ) and ryanodine receptor Lai et al., 1988; Hymel et al., 1988) .
Skeletal muscle contraction is initiated following the release of calcium from terminal cisternae (Somlyo et al., 1985) . Single channel recording studies on sarcoplasmic reticulum membranes incorporated in planar lipid bilayers have shown the existence of two types of Ca2" channels: (i) a low-conductance channel distributed in both free and junctional sarcoplasmic reticulum, and (ii) a high-conductance channel which is selectively localized in terminal cisternae (Smith et al., 1986) . Ca2" flux rates through Ca2" channels of terminal cisternae are compatible with those expected to occur in vivo . The high-conductance Ca2" channel is activated by cis Ca2" and adenine nucleotide and is inhibited by cis (myoplasmic) Mg2" and Ruthenium Red. Single channel recording studies have shown that the only component of such a channel is the ryanodine receptor (Lai et al., 1988; Hymel et al., 1988; Smith et al., 1988) . The kinetics and pharmacological properties of the reconstituted ryanodine receptor Ca2" channel are very similar to those of the Ca2" channel of the native sarcoplasmic reticulum vesicles.
In the last few years, certain functional and structural Vol. 261 properties of cation channels have been elucidated by means of specific antibodies (Meiri et al., 1986; Malouf et al., 1987; Morton et al., 1988; Fitzpatrick et al., 1988) . In the present series of experiments, we used two polyclonal antibodies raised against junctional face membrane proteins and the 350 kDa protein (Volpe et al., 1988) Sarcoplasmic reticulum of fast-twitch rabbit skeletal muscle was isolated and fractionated into light and heavy fractions according to Saito et al. (1984) . Sarcoplasmic reticulum fractionation was carried out in the presence of 100 ,tM-phenylmethanesulphonyl fluoride. Calsequestrincontaining junctional face membrane was isolated by either Triton X-100 or octaethyleneglycolmono-ndodecylether (C12E8) treatment of the terminal cisternae fraction as previously described (Costello et al., 1986) . Calsequestrin was extracted from calsequestrincontaining junctional face membrane by incubation in 10 mM-tris(hydroxymethyl)aminomethane (Tris)/2 mM-EDTA, pH 8.0 (Duggan & Martonosi, 1970) . All fractions were resuspended in 0.3 M-sucrose/5 mM, imidazole, pH 7.4 (buffer A) and stored at -70°C until used. The protein concentration was determined according to Lowry et al. (1951) , using bovine serum albumin as standard. Preparation of anti-(junctional face membrane) and anti-(350 kDa protein) polyclonal antibodies
The anti-(junctional face membrane) serum was raised in hen, by weekly injections into breast muscle of approx. 300 #tg of calsequestrin-free junctional face membrane in buffer A diluted (1: 1) with 1 ml of incomplete Freund's adjuvant. The animal was bled 35 days after beginning the immunization. The immunoglobulins were extracted from preimmune and immune sera as previously described by Orlans et al. (1961) .
The anti-(350 kDa protein) serum was raised in guinea pig as previously described by Volpe et al. (1988) . The anti-(350 kDa protein) polyclonal antibodies were affinity purified according to Bisson & Schiavo (1986) . Preimmune immunoglobulins were purified from guinea pig serum by Sepharose-Protein A chromatography (Goudswaard et al., 1978) .
Immunoblot
Proteins of sarcoplasmic reticulum fractions were electrophoretically resolved according to Laemmli (1970) in SDS/polyacrylamide linear gradient (5-15 %) gels, and then transferred on to nitrocellulose sheets (blots) according to Gershoni et al. (1985) . The Ca2"-dependent ATPase was measured by an enzymecoupled assay following the rate of NADH oxidation in a Perkin Elmer 551 S spectrophotometer (Warren et al., 1974) . The assay was carried out at 37°C in a medium containing, in a final volume of 3 ml, 20 mM-histidine, pH 7.2/100 mM-KCI/5 mM-MgSO4/2 mM-ATP/150 mm-NADH/0.5 mM-phosphoenolpyruvate/5 units of pyruvate kinase/5 units of lactate dehydrogenase, in the presence and absence of 1.5 ,ug of A23187/ml (Zorzato et al., 1985) . The reaction was started by adding approx. 10 ,tg of sarcoplasmic reticulum protein preincubated in the presence or in the absence (control) of antibodies.
Doxorubicin-induced Ca2' release from terminal cisternae was measured as previously described by Palade (1987) by following the differential absorbance (710-790 nm) of the Ca2" indicator Antipyrylazo III in a Hewlett Packard 8451A diode array spectrophotometer. The assay was carried out at 37°C in a medium containing, in a final volume of I ml, 7.5 mM-potassium 1989 Ca2l channels of the junctional sarcoplasmic reticulum pyrophosphate, pH 7.0/1.5 mM-MgATP/250 /tM-Antipyrylazo III / 100 mM-KCI / 5 mM-creatine phosphate, 20 jug of creatine phosphokinase/ml/40 ,g of terminal cisternae protein preincubated in the presence or in the absence (control) of antibodies. Pulses of 20 nmol of CaCl2 were administered to load terminal cisternae vesicles with approx. 2.5,imol of Ca2+ per mg of protein.
When steady state was obtained, Ca2' release was triggered by 100 ,sM-doxorubicin.
Kinetic meaurements of 45Ca2' release were carried out as described by Chu et al. (1988) . Terminal cisternae vesicles previously incubated with anti-(350 kDa protein) antibodies (see above) were actively loaded at 25°C in a medium containing, in a final volume of I ml, 30 gtg of sarcoplasmic reticulum protein/ 100,M-45CaC12 (specific activity about 7000 c.p.m./nmol)/10 mM-MgCl2/80 mM-KCI/20 mM-Tris/Mops, pH 7.0/2 mM-acetyl phosphate. After 2 min, the entire assay medium (1 ml) was filtered through a HAWP 0.45 M Millipore filter, which was then washed with 2 ml of a Mg2" medium [10 mMMgCl2/ 1 mM-Tris / EGTA, 80 mM-KCl/20 mM-Tris / Mops, pH 7.0] at room temperature (22°C) to remove residual uptake medium and acetyl phosphate. The filters retaining the loaded terminal cisternae vesicles were then flushed with various releasing and non-releasing media at different times. The velocity and time of flushing through the filters were electronically controlled by a rapid filtration apparatus (Cosmologic, Olympia, WA, U.S.A.). The radioactivity in the filters was then counted by liquid scintillation spectrometry. The release media contained 80 mM-KCl/20 mM-Tris/Mops, pH 7.0, and either 5,UM free Ca2+ (51.51 1tM-CaCl2/50OsM-Tris/EGTA), ATP (1 mM-Na2ATP/1 mM-Tris/EGTA), or 5 /LM-free Ca2+ and ATP (69.7 1uM-CaCl2/50 /SMTris/EGTA/ 1 mM-Na2ATP). Free ligand concentrations were calculated based on a computer program (Fabiato & Fabiato, 1979) .
Binding of I3Hlryanodine
The binding of ryanodine was carried out as previously described by Fleischer et al. (1985) Photolabelling was carried out as previously described Anti-(junctional face membrane) antibodies comprise the total immunoglobulin fraction, which contains both specific antibodies and other immunoglobulins. We do not exactly know the relative content of specific antibodies against each junctional face membrane protein. Thus, the actual anti-(junctional face membrane) antibodies/terminal cisternae ratio is lower than that reported. Throughout the text, when we indicate the anti-(junctional face membrane) antibodies/terminal cisternae ratio, we refer to the protein/protein ratio between the total immunoglobulin fraction and the terminal cisternae.
RESULTS

Characterization of anti-(junctional face membrane) and anti-(350 kDa protein) polyclonal antibodies
Polyclonal antibodies against calsequestrin-free junctional face membrane and the 350 kDa protein were produced in hens and guinea pigs respectively. The specificity of both antibodies was ascertained by Western blot. Fig. 1 shows the indirect immunoenzymatic staining with anti-(junctional face membrane) (lanes a, b and c) and anti-(350 kDa protein) antibodies (lanes d and e) and the Ponceau Red staining (f and g) of longitudinal sarcoplasmic reticulum (a, d and f), terminal cisternae (b) and calsequestrin-containing junctional face membrane (c, e and g). Comparison between lanes (Fig. 1 Ca2`loading was measured in the presence (A) and in the absence (A) of 10 gM-Ruthenium Red, as described in the Experimental section. Data from two different terminal cisternae preparations were averaged. Control Ca2+ loading rates were 0.25 and 1.04 ,umol of Ca2+/min per mg of protein in the absence and in the presence of Ruthenium Red respectively. JFM, junctional face membrane.
(junctional face membrane) or anti-(350 kDa protein) antibodies (at an antibody/terminal cisternae protein ratio of 1:1). After SDS/polyacrylamide-gel electrophoresis, each gel lane was sliced and radioactivity counted. The photoaffinity labelling profile (Fig. 2) ). This possibility was tested by studying the effect of anti- Effect of anti-(junctional face membrane) antibodies on doxorubicin-induced Ca2" release, Ca2"-dependent ATPase and Ca2" loading rates Fig. 3 shows that the anti-(junctional face membrane) antibodies inhibited the Ca2"-releasing action of doxorubicin. A half-maximal effect was obtained by preincubating terminal cisternae at an antibody/terminal cisternae protein ratio of 1:1. In addition, Fig. 3 shows that the anti-(junctional face membrane) antibodies did not affect the Ca2" dependent ATPase rate in the presence of the Ca2" ionophore A23187, and the Ca2" loading rate in the presence or in the absence of Ruthenium Red. Doxorubicin-induced Ca2" release was either slightly reduced (50 at an immunoglobulin/terminal cisternae protein ratio of 5: 1) or unaffected when terminal cisternae were preincubated with preimmune immunoglobulin and junctional face membrane-preadsorbed anti-(junctional face membrane) antibodies (antibody/ junctional face membrane protein ratio of 1: 1) respectively.
The inhibition of doxorubicin-induced Ca2" release by anti-(junctional face membrane) antibodies might be due to a negligible amount (undetectable by immunoblot) of antibodies against non-junctional sarcoplasmic reticulum protein(s). This possibility was ruled out by carrying out an experiment in which anti-(junctional face membrane) antibodies were adsorbed with longitudinal sarcoplasmic reticulum (antibodies/longitudinal sarcoplasmic reticulum protein ratio of 1: 1). After such treatment, the anti-(junctional face membrane) antibodies were still able to block doxorubicin-induced Ca2" release, with a slightly reduced effectiveness (results not shown).
Effect of anti-(350 kDa protein) affinity-purified antibodies on Ca2"-dependent ATPase and Ca2" loading rates In order to test whether the 350 kDa protein, one of the doxorubicin-binding proteins, is involved in the mechanism of Ca2" release, we studied the effect of anti-(350 kDa protein) antibodies on the functional properties of terminal cisternae. The Ca2" loading rate of terminal cisternae was partially inhibited by anti-(350 kDa protein) antibodies (Fig. 4b, 0) . The Ca2+ loading rate is the net difference between Ca21 influx mediated by the Ca2+ pump and Ca2' efflux via the Ca2+ channel and/or other efflux pathways. Thus, the effect of anti-(350 kDa protein) antibodies on Ca2+ loading might be due either to inhibition of the Ca2+-ATPase, activation of Ca2' efflux, or both. The experiment of Fig. 4(b) Effect of anti-(350 kDa protein) antibodies on doxorubicin-induced Ca2l release Both control terminal cisternae and terminal cisternae preincubated with antibodies were loaded with about 2.5,mol of Ca2"/mg of protein. Doxorubicin-induced Ca2" release was measured spectrophotometrically according to Palade (1987) . Fig. 4(a) shows that anti-(350 kDa protein) antibodies prevent doxorubicin stimulation of Ca2" release. Half-maximal inhibition was obtained at an antibody/terminal cisternae ratio of 0.5. Doxorubicin acts on caffeine-sensitive Ca2" channels (Zorzato et al., 1985; Palade, 1987) and induces Ca2" release via channels which are allosterically regulated by Ca2+, Mg2+ and ATP. Thus, the effect of anti-(350 kDa protein) antibodies on doxorubicin-induced Ca2" release might be due, at least in part, to changes in Ca2"-channel regulation. Kinetic Terminal cisternae (TC) (0.6 mg of protein/ml) were preincubated with (*, *) and without (0, A) antibodies (0.6 mg of protein/ml) in buffer A for 10 min at 25°C, prior to dilution into the 45Ca2" loading medium, as described in the Experimental section. The filters retaining the loaded terminal cisternae vesicles were exposed to various release media for different times as indicated on the abscissa. Results of a representative experiment are shown. Similar effects were observed when terminal cisternae were preincubated with antibodies in PBS or in 45Ca2+ loading medium (at an antibody/terminal cisternae protein ratio of 1: 1). Ca2" release under conditions in which the Ca2+ pump is uninfluent. Fig. 5 shows that Ca2"-induced Ca2" release from control terminal cisternae was inhibited by Mg2" and potentiated by ATP. In the absence of Ca2", ATP itself was a potent Ca2" releasing agent (Fig. Sb) .
Preincubation of terminal cisternae vesicles with anti-(350 kDa protein) antibodies (at an antibody/terminal cisternae protein ratio of 1: 1) decreased both the rate and extent of Ca2"-induced Ca2" release ( 
DISCUSSION
The ryanodine receptor is comprised of four 350 kDa feet protein subunits, which form a cation channel in planar lipid bilayer (Lai et al., 1988) . The pharmacological sensitivity, conductance and selectivity of the ryanodine receptor channel closely match those of the Ca2`channels of intact sarcoplasmic reticulum vesicles (Lai et al., 1988; Smith et al., 1988) . However, other experimental approaches have suggested that additional sarcoplasmic reticulum proteins might be part of, or regulative components of, the native sarcoplasmic reticulum Ca2`channels (Campbell & MacLennan, 1982; Morii et al., 1986; Meszaros et al., 1987; Shoshan-Barmatz, 1987; Rubstov & Murphy, 1988) . In a previous report, Zorzato et al. (1986) (Fig. 2) , and affinity-purified anti-(350 kDa protein) antibodies did not cross-react with proteins in the 170 kDa range on Western blot of terminal cisternae (Volpe et al., 1988;  Fig. 1 ). Thus, it would seem that the 170 kDa doxorubicin-binding protein is distinct from the major proteolytic fragment of the spanning protein, and is possibly a unique component of the native sarcoplasmic reticulum Ca2l channel. In this context, it is worth mentioning that a protein with a similar molecular mass, selectively localized in the heavy sarcoplasmic reticulum, has been proposed to be the caffeine receptor of the sarcoplasmic reticulum Ca2" channel (Rubstov & Murphy, 1988) .
In the second set of experiments, we studied the effect of affinity-purified anti-(350 kDa protein) antibodies on Ca2l release. We have focused our attention on the 350 kDa doxorubicin-binding protein, since it is most probably the same polypeptide which binds other modulators of Ca2" release, including ryanodine (Lai et al., 1987; Inui et al., 1987; Campbell et al., 1987) , ATP (Lai et al., 1988; Imagawa et al., 1987) and calmodulin . Upon preincubation of terminal cisternae with anti-(350 kDa protein) antibodies, Ca2" loading became partially uncoupled from ATP hydrolysis (Fig.  4b) Ca2+/ATP-gated Ca2+ channels (Palade, 1987 protein) antibodies prevent the Ca2l-dependent activation of the channels (Fig. 5a ). When terminal cisternae were preincubated with anti-(350 kDa protein) antibodies, the first-order rate constant of Ca2"-induced Ca2l release was reduced, on average, by 60 %. Interestingly, anti-(350 kDa) protein) antibodies affected neither the stimulation by ATP nor the inhibition by millimolar concentrations of Mg2" (Fig. 5) . If the inhibition of Ca2+-induced Ca2" release is due to the interaction of the anti-(350 kDa protein) antibodies with the Ca2"-activating site(s) of the channel, it is tempting to speculate that the distance between the Ca2"-activating site(s) and the other allosteric sites roughly corresponds to the size of an Ig molecule. In addition, these results indicate that the doxorubicin and Ca2" activating site(s) is (are) in close proximity to each other.
In conclusion, this study shows that the native Ca2+-gated Ca21 channels are restricted to the junctional face membrane of sarcoplasmic reticulum. It remains to ascertain, however, if the ryanodine receptor is the only subunit of such a Ca2+ release channel.
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